pharmaplanter technologies inc

PharmaPlanter Technologies is a platform biotechnology company based in Burnaby, British Columbia, focused on translating early-stage scientific discoveries into viable biopharmaceutical products. The company develops integrated platforms including recombinant protein development, iPSC organoid culture, gene editing, and a proprietary gas vesicle (GV) nanoparticle scaffold for therapeutic delivery. By bridging discovery and development through specialized R&D, CRO services, and collaborative growth initiatives, PharmaPlanter aims to support emerging biotech ventures and advance translational innovation. Their technology suite is designed to integrate advanced therapeutic modeling with novel delivery methods, such as mucosal vaccination and personalized cancer immunotherapy.

The company addresses significant medical needs across areas like microbiome restoration, mucosal immunity, oncology, and metabolic regulation. Their clinical and preclinical pipeline includes oral fecal microbiota transplantation for gastrointestinal disorders, nasal gas vesicle-based vaccines for respiratory viruses, and intradermal cancer immunotherapies. By providing the infrastructure and scientific expertise necessary for complex drug development, PharmaPlanter enables its partners and clients to navigate the transition from scientific theory to clinical application, utilizing targeted delivery kinetics to optimize immune responses and therapeutic efficacy.